

Financial news for BTX dated on 2019-08-08: BioTime Q2 EPS \$(0.2) May Not Compare To \$(0.05) Estimate, Sales \$779K Miss \$990K Estimate

Financial news for BTX dated on 2019-07-11: BioTime Reports Initiation Of Dosing In Phase I/IIa Study Of OpRegen For Treatment Of Dry-AMD Utilizing Orbit Subretinal Delivery System

Financial news for BTX dated on 2019-07-02: Tesla, Unum Therapeutics Making Big Moves In Tuesday's After-Hours Session

Financial news for BTX dated on 2019-07-02: BioTime shares are trading higher after the company conducted the sale of 2.25 million shares in OncoCyte Corp at \$2 per share.

Financial news for BTX dated on 2019-07-02: BioTime Conducts Sale Of Shares In OncoCyte Corporation; Sells 2.25M Shares At \$2/Share

Financial news for BTX dated on 2019-06-14: Raymond James Reinstates Market Perform on BioTime

Financial news for BTX dated on 2019-05-10: BioTime Wins \$2.5M Grant From Israel Innovation Authority for Continued Development Of OpRegen

Financial news for BTX dated on 2019-05-09: BioTime Q1 EPS \$0.30 Beats \$(0.06) Estimate, Sales \$900K Miss \$910K Estimate

Financial news for BTX dated on 2019-05-09: The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut

Financial news for BTX dated on 2019-05-06: BioTime Reports Issuance Of US Patent For Method Of Reducing Cavitation In Patients With Acute Spinal Cord Injury

Financial news for BTX dated on 2019-05-02: BioTime Highlights Presentation Of Updated Data from OpRegen Phase I/IIa Clinical Study At The Association For Research In Vision And Ophthalmology Annual Meeting

Financial news for BTX dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for BTX dated on 2019-04-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Financial news for BTX dated on 2019-03-18: BioTime To Present At Oppenheimer & Co. 29th Annual Healthcare Conference On March 20, 2019

Financial news for BTX dated on 2019-03-15: The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

Financial news for BTX dated on 2019-03-14: BioTime Q4 EPS \$(0.35) Misses \$(0.07) Estimate, Sales \$587K Miss \$590K Estimate

Financial news for BTX dated on 2019-03-14: The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering

Financial news for BTX dated on 2019-02-26: BioTime To Present New Data From OpRegen, Vision Restoration Programs At ARVO 2019

Financial news for BTX dated on 2019-02-21: Benzinga's Top Upgrades, Downgrades For February 21, 2019

Financial news for BTX dated on 2019-02-21: H.C. Wainwright Initiates Coverage On BioTime, Inc. Common Stock with Buy Rating, Announces \$4 Price Target

Financial news for BTX dated on 2019-01-30: BioTime Inc. Highlights Recent, Previously Announced, Positive Data From Its Affiliate Company, OncoCyte Corporation

Financial news for BTX dated on 2019-01-24: Maxim Group Initiates Coverage On BioTime, Inc. Common Stock with Buy Rating, Announces \$3 Price Target

Financial news for BTX dated on 2019-01-07: BioTime Enters Exclusive Agreement With Orbit Biomedical Ltd. To Access Device For Sub-Retinal Delivery Of OpRegen Cells For Treatment Of Dry-AMD

Financial news for BTX dated on 2019-01-04: BioTime Names Brandi Roberts CFO

Financial news for BTX dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for BTX dated on 2018-12-17: Stocks Which Set New 52-Week Low Last

Trading Session, Fri., Dec. 14, 2018

Financial news for BTX dated on 2018-12-14: Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018

Financial news for BTX dated on 2018-12-11: Oppenheimer Initiates Coverage On BioTime, Inc. Common Stock with Outperform Rating, Announces \$3.50 Price Target

Financial news for BTX dated on 2018-12-10: Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Financial news for BTX dated on 2018-12-04: Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018

Financial news for BTX dated on 2018-11-29: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018

Financial news for BTX dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for BTX dated on 2018-11-28: BioTime Reports Distribution Of ~12.7M AgeX Shares Owned By Co.

Financial news for BTX dated on 2018-11-27: Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018

Financial news for BTX dated on 2018-11-08: BioTime to Acquire Asterias Biotherapeutics for 0.71 Shares of BioTime for Each Share of Asterias Owned, Worth \$1.49/Share

Financial news for BTX dated on 2018-11-08: BioTime, Inc. Q3 EPS \$0.53 Beats \$(0.07) Estimate, Sales \$982K Beat \$680K Estimate

Financial news for BTX dated on 2018-11-05: BioTime Announces it Receives its Second \$10.8M Payment From Juvenescence

Financial news for BTX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for BTX dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for BTX dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for BTX dated on 2018-10-29: BioTime Reports Presentation Of New OpRegen Data At American Academy of Ophthalmology Annual Meeting: Continues To Be Well Tolerated With Signs Of Structural Improvement In Retina, Decrease Of Drusen Density Observed In Some Patients

Financial news for BTX dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for BTX dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for BTX dated on 2018-10-11: Stocks Which Set New 52-Week Low Yesterday, October 10th

Financial news for BTX dated on 2018-09-21: BioTime Warrants to Expire on October 1, 2018

Financial news for BTX dated on 2018-09-18: BioTime Names Brian Culley CEO

Financial news for BTX dated on 2018-08-16: AgeX Therapeutics Acquires Technology To Regulate Immune Tolerance

Financial news for BTX dated on 2018-08-02: BioTime Q2 EPS \$(0.03) Beats \$(0.08) Estimate, Sales \$2.55M Beat \$560K Estimate

Financial news for BTX dated on 2018-08-02: BioTime Announces an Independent Investigator Initiated a Study of Premvia

Financial news for BTX dated on 2018-08-02: BioTime to Receive \$43M From Juvenescence

Financial news for BTX dated on 2018-08-01: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BTX dated on 2018-07-24: 38 Biggest Movers From Yesterday

Financial news for BTX dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for BTX dated on 2018-06-29: BioTime Reports Winning Of ~\$743K Grant From Small Business Innovation Research Program Of National Institutes Of Health For Second Year Of Funding To Advance Retinal Restoration Program

Financial news for BTX dated on 2018-06-11: BioTime Inc. Subsidiary, AgeX Therapeutics, Closes \$5 Million Strategic Investment From Juvenescence; Co. Says Juvenescence Investment Combined With Other Capital Raising Efforts Provide Sufficient Capital For Continued Development Of Programs Into 2020

Financial news for BTX dated on 2018-06-08: BioTime Announces Submission Of Draft Registration Statement For Proposed Distribution Of Its AgeX Shares

Financial news for BTX dated on 2018-05-29: BioTime Announces \$1.9 Million Grant From Israel Innovation Authority For Continued Development Of OpRegen For Dry-AMD

Financial news for BTX dated on 2018-05-24: BioTime Reports Opening Of 2 Added US Sites For Clinical Trial Of OpRegen In Dry-AMD

Financial news for BTX dated on 2018-05-11: Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again

Financial news for BTX dated on 2018-05-10: BioTime Q1 EPS \$(0.50) Misses \$(0.07) Estimate, Sales \$701K Miss \$710K Estimate

Financial news for BTX dated on 2018-05-10: Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results

Financial news for BTX dated on 2018-05-06: The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Financial news for BTX dated on 2018-05-02: AgeX Wins a \$386K Grant From the National Institutes of Health

Financial news for BTX dated on 2018-05-01: UPDATE: BioTime Says OpRegen Data Showed There Were No Treatment-Related Systemic Serious Adverse Events

Financial news for BTX dated on 2018-05-01: BioTime Offers Updated OpRegen Trial Data At ARVO: Showed Both Surgical Procedure, Opregen Cells Were Generally Well Tolerated

Financial news for BTX dated on 2018-04-29: The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Financial news for BTX dated on 2018-04-06: 34 Biggest Movers From Yesterday

Financial news for BTX dated on 2018-04-05: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for BTX dated on 2018-03-15: BioTime Reports Q4 EPS \$(0.58) vs \$(0.05) In Same Qtr. Last Year, Sales \$1M vs \$940K Est.

Financial news for BTX dated on 2018-03-15: BioTime Q4 Earnings Outlook

Financial news for BTX dated on 2018-03-13: BioTime Submits CE Mark Application for European Approval of Renevia

Financial news for BTX dated on 2018-02-13: BIO CEO & Investor Conference Concludes Today, With CEL-SCI, Cue Biopharma, and Biotime Among Those Attending

Financial news for BTX dated on 2018-02-02: Watching Shares of BioTime; Hearing Initiated At Buy By Lake Street

Financial news for BTX dated on 2018-02-02: Lake Street Initiates Coverage On BioTime with Buy Rating, Announces \$8.00 Price Target

Financial news for BTX dated on 2018-01-29: BioTime Shares Spike Higher, Up ~\$0.14 Over Last Min. As Hearing Positive Mention From Agora Financial Newsletter

Financial news for BTX dated on 2018-01-22: BioTime Gives 2018 Targets

Financial news for BTX dated on 2018-01-17: BioTime Reports Issuance Of 41 New Patents

Financial news for BTX dated on 2017-12-11: BioTime 8-K Shows Named Aditya Mohanty Sole Pres; Mohanty, Michael West Will Continue To Serve As Co CEOs

Financial news for BTX dated on 2017-12-04: BioTime Offered Added Renevia Data From Successful Pivotal Trial At IFATS Conference; Co. Sees European CE Mark Submission During Q1'18

Financial news for BTX dated on 2017-11-09: BioTime Reports Q3 EPS \$0.12 vs \$(0.09) Est., Sales \$1.68M vs \$270K Est.

Financial news for BTX dated on 2017-10-13: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for BTX dated on 2017-10-13: BioTime Price 9.61M Share Offering At \$2.60/Share

Financial news for BTX dated on 2017-10-13: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for BTX dated on 2017-10-12: BioTime Announces Offering Common Stock, No Size Disclosed

Financial news for BTX dated on 2017-09-26: BioTime Says it Has Enough Data to File for a CE Mark for Renevia by the End of 2017

Financial news for BTX dated on 2017-09-26: Asterias Gets Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer

Financial news for BTX dated on 2017-09-18: 22 Stocks Moving In Monday's Pre-Market Session

Financial news for BTX dated on 2017-09-18: BioTime Awarded \$1.56M Grant from the National Institutes of Health

Financial news for BTX dated on 2017-08-14: Bio Time Recieves \$2M Grant for Development of OpRegen(r) for Dry-AMD

Financial news for BTX dated on 2017-08-02: BioTime, Inc. Subsidiary AgeX Therapeutics Obtains \$10 Million in Capital and Commences Operations

Financial news for BTX dated on 2017-07-25: BioTime Reports Received DSMB Approval To Begin Third Patient Cohort In Trial For Dry-AMD; Begins Enrollment In US

Financial news for BTX dated on 2017-06-19: Biotime Gives Update on Ophthalmology Portfolio

Financial news for BTX dated on 2017-06-16: Biotime Files for Resale of Up to 4.92M Shares By Selling Shareholders - S-3

Financial news for BTX dated on 2017-06-14: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for BTX dated on 2017-05-22: BioTime Shares Now Up 5.5%; Upside Related to Positive News on OncoCyte's Lung Cancer Blood Test

Financial news for BTX dated on 2017-05-22: Biotime Pops to High of \$3.28 on Volume

Financial news for BTX dated on 2017-05-10: BioTime Reports Q1 EPS \$0.46 May Not Compare To \$(0.09) Est., Sales \$0.4M vs \$0.5M Est.

Financial news for BTX dated on 2017-05-09: BioTime Announces 'Positive' Data from OpRegen Trial

Financial news for BTX dated on 2017-05-08: BiotTime OpRegen Phase 1/2a Trial Data To Be Presented At Annual Meeting Of Association For Research In Vision And Ophthalmology Today 3:45pm ET

Financial news for BTX dated on 2017-04-06: S-3 from BioTime Shows Registration for \$75M Mixed Securities Shelf Offering

Financial news for BTX dated on 2017-04-06: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for BTX dated on 2017-03-31: BioTime Shares Up 4+% Following Earlier Initiation of Coverage at Outperform with \$6 Price Target by Raymond James

Financial news for BTX dated on 2017-03-16: BioTime Reports Q4 EPS \$(0.05) vs \$(0.14) Est., Sales \$1.08M vs \$1M Est.

Financial news for BTX dated on 2017-03-13: BioTime Expands Clinical Trial with Two US Sites

Financial news for BTX dated on 2017-02-10: 20 Biggest Mid-Day Losers For Friday

Financial news for BTX dated on 2017-02-10: Mid-Day Market Update: Infinera Surges On Earnings Beat; ChannelAdvisor Shares Plunge

Financial news for BTX dated on 2017-02-10: BioTime Prices Offering of 6.5M Shares of Common Stock at \$2.70/Share

Financial news for BTX dated on 2017-02-10: 30 Stocks Moving In Friday's Pre-Market Session

Financial news for BTX dated on 2017-02-09: BioTime Proposes Public Offering Common Stock, No Size Disclosed

Financial news for BTX dated on 2017-02-06: BioTime Increases Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center

Financial news for BTX dated on 2017-01-10: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for BTX dated on 2016-12-28: Ascendance Biotechnology Licenses the Right to Manufacture, Market, and Sell Cytiva Cardiomyocytes

Financial news for BTX dated on 2016-12-14: BioTime Achieves Patient Recruitment Milestone in Renevia Trial

Financial news for BTX dated on 2016-12-05: Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell

Financial news for BTX dated on 2016-12-01: Recro Pharma CEO Discusses Strong Results In Non-Opioid Pain Treatment Study

Financial news for BTX dated on 2016-11-30: Eyegate CEO Discusses De Novo Pathway For Therapeutic Eye Drops

Financial news for BTX dated on 2016-11-28: Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge

Financial news for BTX dated on 2016-11-28: Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher

Financial news for BTX dated on 2016-11-28: Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy Valtech Cardio

Financial news for BTX dated on 2016-11-22: BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington

Financial news for BTX dated on 2016-11-21: BioTime CEO Shares Updates On Spinal Cord Injury And Dry AMD Therapies

Financial news for BTX dated on 2016-11-20: BioTime CEO Explains Stem Cells And How The Company Uses Them

Financial news for BTX dated on 2016-11-18: BioTime Announces Positive Early Data from Renevia Pivotal Trial Presented at IFATS Meeting

Financial news for BTX dated on 2016-11-03: BioTime Reports Q3 EPS \$0.30 vs. Est. \$(0.14), Rev. \$1.49M vs. Est. \$1.23M

Financial news for BTX dated on 2016-09-23: Ladenburg Initiates BioTime Shares With Buy, \$6 Price Target

Financial news for BTX dated on 2016-09-23: Ladenburg Thalmann Initiates Coverage on BioTime at Buy, Announces \$6.00 PT

Financial news for BTX dated on 2016-09-15: BioTime Reports Affiliate Asterias Biotherapeutics Gave Positive Interim Efficacy Data from Trial in Patients with Complete Cervical Spinal Cord Injuries

Financial news for BTX dated on 2016-08-09: BioTime Reports Q2 EPS \$0.26 (May Not Compare To Est Loss/Share (\$0.17), Rev \$1.3M vs \$1.7M Est

Financial news for BTX dated on 2016-06-16: BioTime Shares Resume Trade, Now Down ~7.7%

Financial news for BTX dated on 2016-06-16: BioTime Prices ~7.322M Share Offering at \$2.39/Share for Gross Proceeds ~\$17.5M

Financial news for BTX dated on 2016-06-16: Shares of BioTime Halted News Pending

Financial news for BTX dated on 2016-06-15: BioTime, Inc. Reports Proposed Public Offering of Common Stock

Financial news for BTX dated on 2016-05-10: BioTime Reports Q1 EPS \$(0.19) vs. Est. \$(0.14), Rev. \$2.07M vs. Est. \$1.43M

Financial news for BTX dated on 2016-02-24: BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia

Financial news for BTX dated on 2016-02-19: Benzinga's Top Initiations

Financial news for BTX dated on 2016-02-19: Chardan Bullish On BioTime, Says Co Has Potential To Be A Significant Competitor In Regenerative Medicine, Co's Advantage Is Knowledge Of Pluripotent Stem Cells

Financial news for BTX dated on 2016-02-19: Chardan Capital Initiates Coverage on BioTime at Buy, Announces \$5.00 PT

Financial news for BTX dated on 2015-12-22: Benzinga's Top Initiations

Financial news for BTX dated on 2015-12-22: Oppenheimer Initiates Coverage on BioTime at Outperform, Announces \$10.00 PT

Financial news for BTX dated on 2015-11-18: BioTime Names Russell Skibsted as New CFO

Financial news for BTX dated on 2015-11-09: BioTime Reports Q3 EPS \$(0.18), Sales \$2.3M

Financial news for BTX dated on 2015-10-19: Biotime Says On October 12, Aditya Mohanty, COO, Was Named Co-President, Co-CEO, Effective October 15

Financial news for BTX dated on 2015-10-02: BioTime, Inc. Agrees to Sell \$5.1M of Equity

Financial news for BTX dated on 2015-09-28: Morning Market Losers

Financial news for BTX dated on 2015-09-28: BioTime Announces Unit Cell Cure Neurosciences Received FDA Fast-Track Designation for OpRegen for Treatment of Dry Form of Age-Related Macular Degeneration

Financial news for BTX dated on 2015-09-16: Amended 13D Filing from Broadwood Partners on BioTime Shows 23.4% Stake

Financial news for BTX dated on 2015-09-14: BioTime To Sell \$8.58M Shares

Financial news for BTX dated on 2015-08-18: Wistar Institute Biotime Unit Oncocyte Corporation Expand Agreement To Develop Molecular Diagnostic Test For Detection Of Lung Cancer -Reuters

Financial news for BTX dated on 2015-08-10: BioTime Reports Q2 Loss \$0.12, no estimates

Financial news for BTX dated on 2015-08-10: BioTime Reports Q2 EPS \$(0.12) vs. Prior Year Quarter \$(0.16)

Financial news for BTX dated on 2015-05-11: BioTime Reports Q1 Loss 0.13, no estimates available

Financial news for BTX dated on 2015-05-11: BioTime Reports Q1 Loss \$0.13, no estimates available

Financial news for BTX dated on 2015-04-27: BioTime's Clinical Grade Stem Cells From Subsidiary ES Cell International to Be Used in Planned CIRM-Funded Preclinical Studies of Huntington's Disease

Financial news for BTX dated on 2015-04-20: BioTime Announces Positive Clinical Results of OncoCyte's PanC-Dx Diagnostic Test

Financial news for BTX dated on 2015-03-18: How Apple ResearchKit Could Change Science Forever

Financial news for BTX dated on 2015-02-27: BioTime Announces First Patient Treated In Pivotal Clinical Trial Of Renevia(TM) For HIV-Associated Lipoatrophy

Financial news for BTX dated on 2015-02-17: BioTime's Cell Cure Neurosciences

Provides Update on Product Development, Partnering Activities

Financial news for BTX dated on 2015-02-04: Asterias Biotherapeutics Announces Public Offering of Common Stock

Financial news for BTX dated on 2015-01-26: BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy

Financial news for BTX dated on 2014-12-29: 8-K from Biotime Shows Aditya Mohanty Named COO

Financial news for BTX dated on 2014-12-15: BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic

Financial news for BTX dated on 2014-12-15: UPDATE: BioTime Appoints Angus C. Russell To Bd Of Directors

Financial news for BTX dated on 2014-12-15: BioTime Appoints Angus C. Russell To Bd Of Directors

Financial news for BTX dated on 2014-11-10: BioTime, Inc. Reports Q3 EPS of \$(0.12); Revenue of \$1.19M

Financial news for BTX dated on 2014-11-04: UPDATE: BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia In Europe

Financial news for BTX dated on 2014-11-04: BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia In Europe

Financial news for BTX dated on 2014-11-03: BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen

Financial news for BTX dated on 2014-10-20: Asterias Biotherapeutics Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury

Financial news for BTX dated on 2014-10-15: Sterne Agee Sees Trouble For Oil Patch Regional Banks

Financial news for BTX dated on 2014-10-09: BioTime Inc. Closes \$31 Million Financing

Financial news for BTX dated on 2014-10-08: UPDATE: Broadwood Had Previously Shown 18.72% Stake in Biotime as of Jul. 22

Financial news for BTX dated on 2014-10-08: Amended 13D Filing from Broadwood Partners on Biotime Shows 21.5% Stake

Financial news for BTX dated on 2014-10-06: BioTime's Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen

Financial news for BTX dated on 2014-10-06: BioTime, Subsidiaries Announce Sale of ~9,431M Shares at \$3.12/Share

Financial news for BTX dated on 2014-10-01: LifeMap Solutions Appoints Rafael Cedeno As CTO

Financial news for BTX dated on 2014-09-11: BioTime Subsidiary, Asterias Biotherapeutics, And Cancer Research UK And Cancer Research Technology Partner For Clinical Trial Of Immunotherapy Vaccine For Lung Cancer

Financial news for BTX dated on 2014-08-27: BioTime Subsidiary Asterias Biotherapeutics Receives U.S. FDA Clearance To Initiate Phase 1/2a Clinical Trial Of AST-OPC1 In Patients With Cervical Complete Spinal Cord Injury

Financial news for BTX dated on 2014-08-12: BioTime Reports Has Received FDA Premarket Notification Clearance for Premvia 510(k)

Financial news for BTX dated on 2014-08-12: BioTime, Inc. Reports Q2 EPS of \$(0.16), Down 14% YOY; Revenue of \$1.11M

Financial news for BTX dated on 2014-07-31: BioTime To Start Multi-Site Clinical Trial For Bladder Cancer Diagnostics

Financial news for BTX dated on 2014-06-18: Biotime Shareholder Broadwood Partners Buys 1,000,000 Shares @\$2.50/Share -Form 4

Financial news for BTX dated on 2014-06-17: BioTime's Asterias Announces \$13M Equity Offering

Financial news for BTX dated on 2014-06-17: Asterias Biotherapeutics Announces Stock Purchase Agreement with CEO For 200,000 Shares at \$2.34/Share

Financial news for BTX dated on 2014-06-12: BioTime Announces Pedro Lichtinger CEO

Financial news for BTX dated on 2014-05-30: BioTime Announces Reviving \$14.3M Grant

Financial news for BTX dated on 2014-05-09: Geron Announces May 28, 2014 as Record Date for Distribution of Asterias Series A Common Stock

Financial news for BTX dated on 2014-03-26: Form 8-K from Biotime Shows Equity Offering Deal Amended to Add Up to 15M Shares

Financial news for BTX dated on 2014-01-27: BioTime, Subsidiary OncoCyte Announce Clinical Development of Bladder Cancer Diagnostics in US, China

Financial news for BTX dated on 2013-10-28: BioTime Unit Asterias Planning to File Registration Statement for Underwritten Public Shares, Expecting Proceeds in \$12-15M Range

Financial news for BTX dated on 2013-10-28: BioTime Halted News Pending

Financial news for BTX dated on 2013-08-09: BioTime, Inc. Reports Q2 EPS of \$(0.14)

Financial news for BTX dated on 2013-08-08: BioTime, Inc. Reports Q2 EPS of \$0.62; Revenue of \$143.60M

Financial news for BTX dated on 2013-08-05: BioTime's Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIPl as a Breast Cancer-Specific Marker

Financial news for BTX dated on 2013-06-03: BioTime Says Will Raise \$9M in Registered Direct Offering

Financial news for BTX dated on 2013-05-13: BioTime, Inc. Reports Q1 EPS of \$(0.15); Revenue of \$614.50K; BioTime Unit Rceives \$1.5M Grant

Financial news for BTX dated on 2013-05-09: BioTime, Inc. Reports Q1 EPS of \$0.36; Revenue of \$91.80M

Financial news for BTX dated on 2013-04-23: LifeMap Sciences Announces Partnership With Appistry

Financial news for BTX dated on 2013-04-19: BioTime Announces License Deal with UCLA

Financial news for BTX dated on 2013-04-10: LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

Financial news for BTX dated on 2013-03-25: BioTime's LifeMap Sciences Launches LifeMap Discovery Version 1.1

Financial news for BTX dated on 2013-03-18: BioTime, Inc. Reports Q4 EPS of \$(0.12), Down 9% YOY; Revenue of \$1.20M vs \$4.0M Est

Financial news for BTX dated on 2013-01-08: Top Narrow Based Indexes For January 8, 2013

Financial news for BTX dated on 2013-01-07: BioTime to Buy Human Embryonic Stem Cell Program Assets of Geron

Financial news for BTX dated on 2012-11-19: Benzinga's Small Cap Movers for Monday November 19, 2012

Financial news for BTX dated on 2012-11-19: Top Narrow Based Indexes For November 19, 2012

Financial news for BTX dated on 2012-11-15: BioTime and BioTime Acquisition Corporation Announce Combined \$10M Financing

Financial news for BTX dated on 2012-11-15: PREVIEW: Geron to Resume Trading at 4:45pm

Financial news for BTX dated on 2012-11-15: UPDATE: BioTime, Geron Enter Deal on Stem Cell Assets

Financial news for BTX dated on 2012-11-15: BioTime Announces Non-Binding Letter of Intent with Geron Regarding Stem Cell Assets

Financial news for BTX dated on 2012-10-19: LifeMap Sciences Appoints Louis Silverman to Board of Directors

Financial news for BTX dated on 2012-10-19: Geron Acknowledges Letter to its Stockholders from BioTime

Financial news for BTX dated on 2012-09-28: Thomas Okarma Appointed CEO of New BioTime Company

Financial news for BTX dated on 2012-08-27: BioTime Obtains Expanded License to HyStem Technology

Financial news for BTX dated on 2012-08-01: BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded \$1.33 Million Grant From Israel's Office of the Chief Scientist

Financial news for BTX dated on 2012-07-31: BioTime Files 868.43K Shares

Financial news for BTX dated on 2012-07-17: BioTime Signs Agreements with Jade Therapeutics for Ophthalmological Drug Delivery Applications of HyStem(r) Technology

Financial news for BTX dated on 2012-05-22: BioTime and Subsidiary LifeMap Sciences Announce Agreement to Market MalaCards

Financial news for BTX dated on 2012-05-14: HyStem-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease

Financial news for BTX dated on 2012-04-23: BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical Development of Vascular Progenitors for the Treatment of Age-Related Vascular Disease

Financial news for BTX dated on 2012-04-23: BioTime and its Subsidiary OrthoCyte Corporation Provides Update on Preclinical Development of OTX-CP07

Financial news for BTX dated on 2012-04-23: BioTime's Subsidiary Cell Cure Neurosciences Provides Update on OpRegen(r) Product Development

Financial news for BTX dated on 2012-04-23: BioTime Provides Update on Renevia™ Product Development; Product Development on Track for CE Marking by 2013

Financial news for BTX dated on 2012-04-23: BioTime Demonstrates Efficient Method for the Manufacture of Cartilage-Producing Cells from Human Embryonic Stem Cells

Financial news for BTX dated on 2012-04-20: BioTime and Subsidiary LifeMap Sciences Announce Agreement to Acquire XenneX

Financial news for BTX dated on 2012-04-12: BioTime Board of Directors Forms Science and Tech Committee

Financial news for BTX dated on 2012-01-24: BioTime Trading 12.8% Higher on Heavy Volume; Currently at \$5.81

Financial news for BTX dated on 2012-01-24: BioTime Spiking to High of Day on Heavy Volume

Financial news for BTX dated on 2012-01-24: BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem Cell Reprogramming

Financial news for BTX dated on 2012-01-03: UPDATE: BioTime Will Produce Products From 5 Human Embryonic Stem Cell Lines From Reproductive Genetics Institute

Financial news for BTX dated on 2012-01-03: BioTime to Produce Stem Cells for Research in Muscle Disorders

Financial news for BTX dated on 2011-12-21: BioTime Signs Agreement with USCNI Life Science to Source Antibody-Based Products

Financial news for BTX dated on 2011-12-20: Microcap Movers for Tuesday December 20, 2011

Financial news for BTX dated on 2011-12-20: BioTime CFO Says 27% Rise in Share Price Due Most Likely to Short Covering after Friday's Press Release on Cancer Diagnostic Test

Financial news for BTX dated on 2011-10-13: BioTime Publishes Paper Describing First Complete Sequencing of the Nuclear DNA of Five Clinical-Grade Human Embryonic Stem Cell Lines

Financial news for BTX dated on 2011-10-04: BioTime Announces Appointment of Chief Financial Officer

Financial news for BTX dated on 2011-09-06: BioTime Enters into Worldwide License Agreement with Cornell University to Develop and Commercialize Vascular Cells Derived from Human Embryonic Stem Cells

Financial news for BTX dated on 2011-08-24: BioTime's Subsidiary OncoCyte Expands Cancer Programs with \$10 Million Equity Financing

Financial news for BTX dated on 2011-08-19: UPDATE: Biotime to Provide Complete Genome Sequences by Fall 2011

Financial news for BTX dated on 2011-08-19: BioTime Receives NIH Approval for Four GMP Human Embryonic Stem Cell Lines

Financial news for BTX dated on 2011-07-19: BioTime Announces the Issuance of a Second U.S. Glycosan Hydrogel Patent

Financial news for BTX dated on 2011-07-15: BioTime Receives \$335,900 SBIR Grant

Financial news for BTX dated on 2011-06-29: BioTime Announces Appointment of Chief Commercial Officer

Financial news for BTX dated on 2011-06-23: Top Narrow Based Indexes For June 23

Financial news for BTX dated on 2011-06-03: BioTime Receives NIH Approval for Two GMP Human Embryonic Stem Cell Lines

Financial news for BTX dated on 2011-05-05: Calls Purchased on BioTime, Inc. (BTX)

Financial news for BTX dated on 2011-05-03: BioTime Initiates Clinical Development Program for HyStem-Rx as a Cell Delivery Device for Reconstructive Surgery and Other Cell-Based Therapies

Financial news for BTX dated on 2011-04-11: Calls Purchased on BioTime, Inc. (BTX)

Financial news for BTX dated on 2011-03-17: Puts Purchased on BioTime, Inc. (BTX)

Financial news for BTX dated on 2011-03-07: Puts Purchased on BioTime, Inc. (BTX)

Financial news for BTX dated on 2011-02-14: BioTime To Acquire Glycosan BioSystems

Financial news for BTX dated on 2011-01-28: BioTime Acquires Assets of Cell Targeting

Financial news for BTX dated on 2011-01-06: BioLogic Equity Opens BTX With Sell